VA
COLL icon

Vident Advisory’s Collegium Pharmaceutical COLL Stock Holding History

Vident Advisory’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$796K Buy
21,999
+6,966
+46% +$238K 0.01% 1104
2026
Q1 		$497K Buy
15,033
+1,900
+14% +$80.4K ﹤0.01% 1260
2025
Q4 		$608K Sell
13,133
-2,333
-15% -$97.6K 0.01% 1056
2025
Q3 		$541K Buy
15,466
+281
+2% +$9.77K 0.01% 1168
2025
Q2 		$449K Sell
15,185
-791
-5% -$22.6K 0.01% 1122
2025
Q1 		$477K Sell
15,976
-922
-5% -$28.2K 0.01% 1059
2024
Q4 		$484K Buy
16,898
+3,672
+28% +$122K 0.01% 969
2024
Q3 		$511K Sell
13,226
-2,055
-13% -$73.3K 0.01% 908
2024
Q2 		$492K Buy
15,281
+7,671
+101% +$266K 0.01% 887
2024
Q1 		$295K Sell
7,610
-145
-2% -$5.07K 0.01% 1030
2023
Q4 		$239K Buy
+7,755
New +$194K 0.01% 1128

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vident Advisory's COLL Position: Q2 2026 in Review

Vident Advisory increased its Collegium Pharmaceutical (COLL) stake by 46% in Q2 2026, buying an estimated $238K and bringing the position to 21,999 shares worth $796K. The position accounts for 0.01% of the portfolio, ranked #1104.

Vident Advisory first reported a position in COLL in Q4 2023 and has held it in 11 quarters since. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Vident Advisory held 21,999 shares of Collegium Pharmaceutical worth $796K as of Q2 2026.
  • Vident Advisory bought 6,966 Collegium Pharmaceutical shares in Q2 2026, an estimated $238K.
  • Collegium Pharmaceutical made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1104 holding.
  • Vident Advisory first reported a position in Collegium Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.